Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Several other equities analysts have also recently weighed in on the company. Oppenheimer set a $28.00 price objective on Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday. HC Wainwright reiterated a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price objective on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Finally, Roth Capital assumed coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Syros Pharmaceuticals has a consensus rating of “Buy” and an average target price of $22.23.
Syros Pharmaceuticals (NASDAQ:SYRS) traded up $0.34 during trading hours on Thursday, hitting $10.73. The stock had a trading volume of 299,600 shares, compared to its average volume of 249,671. Syros Pharmaceuticals has a fifty-two week low of $6.30 and a fifty-two week high of $24.38. The company has a market cap of $280.85 and a PE ratio of -6.17.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53). sell-side analysts expect that Syros Pharmaceuticals will post -2.12 EPS for the current year.
In other news, Director Srinivas Akkaraju bought 109,774 shares of the business’s stock in a transaction on Thursday, December 14th. The shares were purchased at an average price of $9.03 per share, for a total transaction of $991,259.22. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jeremy P. Springhorn bought 15,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was purchased at an average price of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Insiders own 33.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SYRS. Schwab Charles Investment Management Inc. bought a new stake in Syros Pharmaceuticals in the 2nd quarter valued at approximately $343,000. Rhumbline Advisers bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter worth approximately $198,000. Bank of New York Mellon Corp raised its stake in shares of Syros Pharmaceuticals by 157.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after purchasing an additional 18,382 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Syros Pharmaceuticals by 360.5% during the 2nd quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock worth $366,000 after purchasing an additional 17,785 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in shares of Syros Pharmaceuticals by 646.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock worth $553,000 after purchasing an additional 29,782 shares in the last quarter. Hedge funds and other institutional investors own 57.96% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/syros-pharmaceuticals-syrs-rating-lowered-to-hold-at-zacks-investment-research.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.